Dual-Drug Nanosystem: Etoposide Prodrug and Cisplatin Coloaded Nanostructured Lipid Carriers for Lung Cancer Therapy
Min Du,Jianbo Yin
DOI: https://doi.org/10.2147/DDDT.S386100
2022-12-06
Abstract:Min Du, 1 Jianbo Yin 2 1 Department of Pharmacy, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu Province, 214000, People's Republic of China; 2 Department of Pharmacy, Wuxi Dashan Medical Beauty Clinic, Wuxi, Jiangsu Province, 214001, People's Republic of China Correspondence: Jianbo Yin, Email Purpose: Cisplatin (CDDP) and etoposide (Etp) are recommended first-line therapy for lung cancer. Nanostructured lipid carriers (NLCs) are engineered to deliver drugs for lung cancer treatment. In the present study, NLCs were applied to coload an Etp prodrug (EtpP) and CDDP. Methods: The Etp prodrug was synthesized by linking the phenolic hydroxyl group of Etp with polyethylene glycol (PEG). EtpP and CDDP coencapsulated NLCs (EtpP–CDDP NLCs) were prepared using film ultrasound. Cytotoxicity of drugs and drug-containing NLCs was assessed by evaluating cell viability using MTT assays. In vivo antitumor efficiency of EtpP–CDDP NLCs was evaluated on lung cancer–bearing xenografts. Results: EtpP–CDDP NLCs showed a uniformly spherical morphology with a size of 176.8± 4.9 nm and -potential of – 31.9± 3.2 mV. Cellular uptake efficiency of EtpP–CDDP NLCs was 57.4%± 3.9% on A549/DDP cells. EtpP–CDDP NLCs exhibited more sustained plasma retention, the highest drug distribution in tumors, and the highest tumor-inhibition rates in lung tumor–bearing mice. Conclusion: EtpP–CDDP NLCs improved tumor-cell uptake, cytotoxicity, and tumor-inhibition efficiency, and could be used as a promising drug-delivery system for lung cancer combination therapy. Keywords: lung cancer, prodrug, etoposide, cisplatin, nanostructured lipid carriers Lung cancer is the leading cause of cancer death in developed countries, and can be divided into two major classes: non–small cell lung cancer (NSCLC; about 85%) and small-cell lung cancer (about 15%). 1–3 Patients with NSCLC have low overall relative 5-year survival: 25% in the US from 2009 to 2015. 4 On the basis of clinical studies, the National Comprehensive Cancer Network NSCLC Panel recommends cisplatin (CDDP) combined with docetaxel, etoposide (Etp), gemcitabine, or vinorelbine for preoperative and postoperative chemotherapy. 5–7 Arriagada et al found that CDDP plus Etp in patients with completely resected NSCLC improved patient survival by 56.5%. 5 Senan et al used Etp 50 mg/m 2 and CDDP 50 mg/m 2 intravenously on patients with stage IIIA/B unresectable nonsquamous NSCLC randomly. 7 Unfortunately, these nonselective combination chemotherapies with multidrug resistance hindered clinical application. Therefore, major efforts have focused on the development of targeted drug-delivery systems based on prodrugs, nanocarriers, and ligand-modified nanoparticles. CDDP combined with Etp is recommended first-line therapy for NSCLC. 5 CDDP is a cytotoxic antitumor drug. Its main mechanism involves the binding of genomic DNA in the cell nucleus and interfering with transcription to lead to cell death. 8 Its main side effects are nephrotoxicity and peripheral neuropathy. Recently, studies reported that targeted nanocarriers could enhance CDDP's efficacy and reduce its toxicity in healthy cells. 9,10 The topoisomerase II inhibitor Etp inhibits DNA production by affecting the premitotic phase of cell division. 11 Poor solubility and chemical instability are major limits to its clinical application. 12 A prodrug is a kind of compound containing a parent drug that carries out biotransformation in vivo through chemical or enzymatic cleavage, and can effectively transfer active molecules. 13 Prodrug approaches have been developed to modify solubility, increase therapeutic efficacy, and reduce toxicity. 14 Schmidt et al synthesized a glucuronide-based prodrug of Etp that exhibited less cytotoxicity and more water-solubility than Etp itself. 15 In this study, we designed a novel amphiphilic Etp prodrug and tested it on a hydrophobic group (Etp group) and a hydrophilic group (polyethylene glycol, PEG). Nanoparticles have a length of about 1–100 nm. 16 Nanoparticles are attractive for drug delivery because they have important and unique characteristics, such as much larger surface area:mass ratio than other particles, quantum properties, and the ability to adsorb and carry other compounds. 17 Nanoparticles have been exploited to enhance the pharmacokinetic properties and therapeutic effects of drugs. 18 Lipid nanoparticles are colloidal particles composed of biocompatible and biodegradable lipid matrices, among which nanostructured lipid carriers (NLCs) constituted of blends of lipids in solid and liquid state -Abstract Truncated-